Leerink Swann Upgrades Boston Scientific To Outperform
Analysts at Leerink Swann upgraded Boston Scientific Corporation (NYSE: BSX) from Market Perform to Outperform.
The price target for Boston Scientific has been raised from $15 to $18.
Boston Scientific shares have surged 9.78% over the past 52 weeks, while the S&P 500 index has gained 10.22% in the same period.
Boston Scientific's shares rose 2.41% to close at $14.03 yesterday.
Latest Ratings for BSX
Date | Firm | Action | From | To |
---|---|---|---|---|
Feb 2022 | Morgan Stanley | Maintains | Overweight | |
Feb 2022 | Raymond James | Maintains | Strong Buy | |
Feb 2022 | SVB Leerink | Maintains | Market Perform |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Leerink SwannUpgrades Analyst Ratings